A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine

• Main Authors: Van Dyke R., Ngo-Giang-Huong N., Shapiro D., Frenkel L., Britto P., Roongpisuthipong A., Beck I., Yuthavisuthi P., Prommas S., Puthanakit T., Achalapong J., Chotivanich N., Rasri W., Cressey T., Maupin R., Mirochnick M., Jourdain G.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84555209220&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42901
• Institution: Chiang Mai University

Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases...